ArticleScientific reports2015
Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Non-canonical stringent response signaling mediates antimicrobial fatty acid sensitivity inbioRxiv : the preprint server for biology · 2026Article
- RpoB H481Y Rifampicin Resistance Mutation-Associated Oxidative Stress Sensitivity Reduces the Virulence of Staphylococcus aureus.Microbiology and immunology · 2025Article
- Discovery of new AMR drugs targeting modulators of antimicrobial activity using in vivo silkworm screening systems.The Journal of antibiotics · 2025Review
- Article
- Comparative Genomics Identifies Novel Genetic Changes Associated with Oxacillin, Vancomycin and Daptomycin Susceptibility in ST100 Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Efflux pump inhibitor combined with ofloxacin decreases MRSA biofilm formation by regulating the gene expression of NorA and quorum sensing.RSC advances · 2023Article
- Knockout ofJournal of bacteriology · 2022Article
- Serum apolipoprotein A-I potentiates the therapeutic efficacy of lysocin E against Staphylococcus aureus.Nature communications · 2021Article
- Inferring multilayer interactome networks shaping phenotypic plasticity and evolution.Nature communications · 2021Article
- Investigating the effect of an identified mutation within a critical site of PAS domain of WalK protein in a vancomycin-intermediate resistant Staphylococcus aureus by computational approaches.BMC microbiology · 2021Article
- Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus.Communications biology · 2021Article
- Single-nucleotide polymorphisms in a vancomycin-resistant Staphylococcus aureus strain based on whole-genome sequencing.Archives of microbiology · 2020Article
- A new coumarin compound DCH combats methicillin-resistantScience advances · 2020Article
- Gain- and Loss-of-Function Screens Coupled to Next-Generation Sequencing for Antibiotic Mode of Action and Resistance Studies inAntimicrobial agents and chemotherapy · 2019Article
- D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.The Journal of antibiotics · 2017Article
- Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.The Journal of antibiotics · 2017Article
- In Vitro Tolerance of Drug-Naive Staphylococcus aureus Strain FDA209P to Vancomycin.Antimicrobial agents and chemotherapy · 2017Article
- Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents.Frontiers in microbiology · 2017Review
- Colony fingerprint for discrimination of microbial species based on lensless imaging of microcolonies.PloS one · 2017Article
- Molecular Events for Promotion of Vancomycin Resistance in Vancomycin IntermediateFrontiers in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of vancomycin (VCM) resistance in Staphylococcus aureus threatens global health. Studies of the VCM-resistance mechanism and alternative therapeutic strategies are urgently needed. We mutagenized S. aureus laboratory strains and methicillin-resistant S. aureus (MRSA) with ethyl methanesulfonate, and isolated mutants that exhibited high resistance to VCM (minimum inhibitory concentration = 32 μg/ml). These VCM-resistant strains were sensitive to linezolid and rifampicin, and partly to arbekacin and daptomycin. Beta-lactams had synergistic effects with VCM against these mutants. VCM-resistant strains exhibited a 2-fold increase in the cell wall thickness. Several genes were commonly mutated among the highly VCM-resistant mutants. These findings suggest that MRSA has a potential to develop high VCM resistance with cell wall thickening by the accumulation of mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.